This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2001;286:907.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

After years of taking the opposite tack, the American Heart Association (AHA) is recommending that hormone replacement therapy (HRT) should not be initiated for secondary prevention of cardiovascular disease (CVD) in postmenopausal women.

The recommendation follows results from clinical trials suggesting that no overall cardiovascular benefit results, and a possible early increased risk of CVD events occurs, when women with documented atherosclerosis begin to take HRT (estrogen typically combined with a progestin).

The AHA recommendations (Circulation. 2001;104:499-503; online at http://circ.ahajournals.org/cgi/content/full/104/4/499) are needed because physicians have asked for clarification of the data surrounding HRT, said Lori Mosca, MD, PhD, lead author of the AHA science advisory and director of preventive cardiology at New York Presbyterian Hospital in New York City.

"NOT SUFFICIENT EVIDENCE"

"For many years, cardiologists and other health care providers who take care of women have assumed that HRT protects the heart," Mosca said. "At . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers?
Genuis
J Am Board Fam Med 2005;18:419-425.
ABSTRACT | FULL TEXT  

Reproductive History in Women with Lower Limb Ischemia
Hultgren et al.
ANGIOLOGY 2004;55:373-383.
ABSTRACT